ナノ粒子ドラッグデリバリー市場及びパイプラインインサイト

◆英語タイトル:Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
◆商品コード:Kuick-40610
◆発行会社(調査会社):Kuick Research
◆発行日:2014年6月
◆ページ数:475
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User USD2,400 ⇒換算¥273,600見積依頼/購入/質問フォーム
Multi-User(社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。Kuick Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Drug delivery technologies currently occupy a significant position in the pharmaceutical industry. It has become so important that the mode of delivery of drugs has come to define the efficiency and marketability of those drugs. The pharmaceutical industry is witnessing a shift in the focus of the stakeholders towards newer systems of drug delivery in order to achieve efficient and safe transportation of novel products and formulations. There have been many products which have been derived from new delivery systems and are currently attracting the attention of different companies. It has been recognized that the introduction of a new drug delivery system would bring along a potential chance for an existing drug candidate molecule.

The field of nanotechnology is considered to be an exciting area which offers the potential for developing drug delivery systems using nanoparticles, with dimension range of 1-100 nm. These nanoparticles tend to have the ability to deliver an adequate range of molecules to different areas of the body. Additionally, these nanoparticles also posses the capability to deliver the molecules for a comparatively longer duration of time as compared to other routes. The major objectives of a drug delivery system based on nanoparticles, are size of particles, surface properties and discharge of drugs or the active ingredients in order to attain the maximum level of efficiency.

The combination of nanotechnology along with medicine has resulted in potential concepts and ideas for the pharma industry which is set to introduce momentous innovations in the fight against different diseases. The two concepts of therapeutic nanocarriers – liposomes and albumin nanoparticles are gaining prominence rapidly and would soon become well-established in the market across the globe. The need of the hour currently is to obtain a deeper understanding of the biodistribution of nanoparticles, which is influenced mainly by their ability to negotiate biological barriers.

Additionally, a significant growth of this field would mostly depend on the strong establishment of a toxicology database which would support the safety determinations and risk assessments. This database could possibly include toxicity as a function of material, size, shape, cell type or animal, duration of exposure and the methods which are used to assay toxicity. Also, there needs to be a mechanism wherein the scaling up of production levels of drug particles is enabled. Finally, this database should also consider protocols relating to storage and handling. The use of such a compact database would help the pharma industry to translate biomedical nanotechnology from the laboratory to the general public at ease.

“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:

• Nanoparticle Drug Delivery Market Overview
• Nanoparticle Drug Delivery Mechanism
• Clinical Pipeline by Phase & Target Indications
• Drug Profiles in Report: 190
• Majority of Nanoparticle Drug in Preclinical Phase: 70
• Marketed Nanoparticle Drugs: 12
• Suspended & Discontinued Drug Profiles

【レポートの目次】

1. Introduction to Nanoparticle Technology for Drug Delivery

2. Nanoparticle Drug Delivery Mechanism
2.1 Protein Based Delivery Systems
2.2 Natural Polymers & Derivates
2.3 Polymeric Carriers
2.4 Dendrimers
2.5 Fullerene
2.6 Carbon Nanotubes

3. Application of Nanotechnology for Drug Delivery

4. Nanoparticle Drug Delivery Market Overview
4.1 Market Overview
4.2 Clinical Insight

5. Nanoparticle Drug Delivery Market Dynamics
5.1 Drivers
5.2 Challenges
5.3 Future Outlook

6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. Marketed Nanoparticle Drug

8. Suspended & Discontinued Nanoparticle Drug Profiles
8.1 No Development Reported
8.2 Discontinued
8.3 Suspended

9. Competitive Landscape
9.1 Abraxis BioScience
9.2 Access Pharmaceuticals
9.3 Alnylam Pharmaceuticals
9.4 Arrowhead Research
9.5 BIND Biosciences
9.6 iCeutica
9.7 NanoCarrier
9.8 Nippon Kayaku
9.9 Nanobiotix
9.10 Samyang

Figure 1-1: Nanoparticle Technology for Drug Delivery
Figure 1-2: Nanoparticle Class
Figure 2-1: Nanoparticle Drug Delivery System
Figure 4-1: Nanoparticle Drug Delivery Market (US$ Billion), 2013-2020
Figure 4-2: Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-3: Number Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-4: No Development in Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-5: Number of No Development in Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-6: Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-7: Number of Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-8: Suspended Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-9: Number of Suspended Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 9-1: Arrowhead Research Corporation Clinical Pipeline
Figure 9-2: NanoCarrier Clinical Pipeline



★調査レポート[ナノ粒子ドラッグデリバリー市場及びパイプラインインサイト]販売に関する免責事項
★調査レポート[ナノ粒子ドラッグデリバリー市場及びパイプラインインサイト]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆